Insulin resistance in polycystic ovary syndrome: Treating a phenotype without a genotype

Molecular and Cellular Endocrinology

Volumn 145, Issue 1-2, 1998, Pages 103-110

  Legro, Richard S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Glucose tolerance; Hyperandrogenism; Insulin resistance; Polycystic ovary syndrome; Type 2 diabetes mellitus

Indexed keywords

CONFERENCE PAPER; FEMALE; GENOTYPE; GLUCOSE TOLERANCE; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL;

FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; PREVALENCE; WEIGHT LOSS;

EID: 0032566957     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(98)00176-2     Document Type: Conference Paper

References (54)

1. Acbay O., Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil. Steril. 65:1996;946-949.
2. American Diabetic Association, 1998. Consensus development conference on insulin resistance: 5-6 November 1997. Diabetes Care 21, 310-314.
3. Braun B., Zimmermann M.B., Kretchmer N. Effects of exercise intensity on insulin sensitivity in women with non-insulin-dependent diabetes mellitus. J. Appl. Physiol. 78:1995;300-306.
4. Burghen G.A., Givens J.R., Kitabchi A.E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 50:1980;113-116.
5. Chang R.J., Nakamura R.M., Judd H.L., Kaplan S.A. Insulin resistance in nonobese patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 57:1983;356-359.
6. Chasen-Taber L., Willett W.C., Stampfer M.J. et al. A prospective study of oral contraceptives and NIDDM among US women. Diabetes Care. 20:1997;330-335.
7. Ciaraldi T.P., el-Roeiy A., Madar Z., Reichart D., Olefsky J.M., Yen S.S. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 75:1992;577-583.
8. Crave J.C., Fimbel S., Lejeune H., Cugnardey N., Dechaud H., Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J. Clin. Endocrinol. Metab. 80:1995;2057-2062.
9. Dahlgren E., Johansson S., Lindstedt G. et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil. Steril. 57:1992;505-513.
10. Donesky B.W., Adashi E.Y. Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy. Fertil. Steril. 63:1995;439-463.
11. Dunaif A., Finegood D.T. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81:1996;942-947.
12. Dunaif A., Hoffman A.R., Scully R.E., Flier J.S., Longcope C., Levy L.J. Jr. Clinical, biochemical, and ovarian morphologic features in women with acanthosis nigricans and masculinization. Obstet. Gynecol. 66:1985;545-552.
13. Dunaif A., Segal K.R., Futterweit W., Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38:1989;1165-1174.
14. Dunaif A., Givens J.R., Haseltine F.P., Merriam G.R. Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism). 1992;Blackwell, Boston.
15. Dunaif A., Segal K.R., Shelley D.R., Green G., Dobrjansky A., Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 41:1992;1257-1266.
16. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81:1996;3299-3306.
17. Ehrmann D.A., Sturis J., Byrne M.M., Karrison T., Rosenfield R.L., Polonsky K.S. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J. Clin. Invest. 96:1995;520-527.
18. Ehrmann D.A., Schneider D.J., Sobel B.E., Cavaghan M.K., Imperial J., Polonsky K.S. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82:1997;2108-2116.
19. Ehrmann D.A., Cavaghan M.K., Imperial J., Sturis J., Rosenfield R.L., Polonsky K.S. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82:1997;524-530.
20. Ek I., Arner P., Bergqvist A., Carlstrom K., Wahrenberg H. Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: a possible link to insulin resistance? J. Clin. Endocrinol. Metab. 82:1997;1147-1153.
21. Farquhar C.M., Birdsall M., Manning P., Mitchell J.M., France J.T. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust. NZ J. Obstet. Gynecol. 34:1994;67-72.
22. Flier J.S., Eastman R.C., Minaker K.L., Matteson D., Rowe J.W. Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes. Diabetes. 34:1985;101-107.
23. Franks S., Kiddy D., Sharp P. et al. Obesity and polycystic ovary syndrome. Ann. NY Acad. Sci. 626:1991;201-206.
24. Greenblatt E., Casper R.F. Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome. Am. J. Obstet. Gynecol. 156:1987;279-285.
25. Guzick D.S., Wing R., Smith D., Berga S.L., Winters S.J. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil. Steril. 61:1994;598-604.
26. Haffner S.M. Impaired glucose tolerance, insulin resistance, and cardiovascular disease. Diabetic Med. 14(Suppl 3):1997;12-18.
27. Holte J., Bergh T., Berne C., Wide L., Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80:1995;2586-2593.
28. Jaatinen T.A., Anttila L., Erkkola R. et al. Hormonal responses to physical exercise in patients with polycystic ovarian syndrome. Fertil. Steril. 60:1993;262-267.
29. Katz M., Carr P.J., Cohen B.M., Millar R.P. Hormonal effects of wedge resection of polycystic ovaries. Obstet. Gynecol. 51:1978;437-444.
30. Kiddy D.S., Hamilton-Fairley D., Seppala M. et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin. Endocrinol. 31:1989;757-763.
31. Kiddy D.S., Hamilton-Fairley D., Bush A., Short F., Anyaoku V., Reed M.J. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. 36:1992;105-111.
32. Korytkowski M.T., Mokan M., Horwitz M.J., Berga S.L. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80:1995;3327-3334.
33. Legro, R.S., Finegood, D.T., Dunaif, A., 1998. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab. In Press.
34. Modan M., Harris M.I., Halkin H. Evaluation of WHO and NDDG criteria for impaired glucose tolerance: results from two national samples. Diabetes. 38:1989;1630-1635.
35. Morin-Papunen L.C., Koivunen R.M., Ruokonen A., Martikainen H.K. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil. Steril. 69:1998;691-696.
36. Nader S., Riad-Gabriel M.G., Saad M.F. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J. Clin. Endocrinol. Metab. 82:1997;3074-3077.
37. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450C17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New Engl. J. Med. 335:1996;617-623.
38. Nestler J.E., Barlascini C.O., Matt D.W. et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 68:1989;1027-1032.
39. Nestler J.E. Insulin regulation of human ovarian androgens. Hum. Reprod. 12(Suppl 1):1997;53-62.
40. Okajima T., Koyanagi T., Goto M., Kato K. Hormonal abnormalities were improved by weight loss using very low calorie diet in a patient with polycystic ovary syndrome (Japanese). Fukuoka Igaku Zasshi. 85:1994;263-266.
41. O'Meara N.M., Blackman J.D., Ehrmann D.A. et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 76:1993;1241-1247.
42. Pasquali R., Casimirri F., Plate L., Capelli M. Characterization of obese women with reduced sex hormone-binding globulin concentrations. Horm. Metab. Res. 22:1990;303-306.
43. Polson D.W., Adams J., Wadsworth J., Franks S. Polycystic ovaries - a common finding in normal women. Lancet. 1:1988;870-872.
44. Prelevic G.M., Wurzburger M.I., Balint-Peric L., Nesic J.S. Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet. 336:1990;900-903.
45. Reaven G.M. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
46. Rittmaster R.S. Hirsutism. Lancet. 349:1997;191-195.
47. Robinson S., Kiddy D., Gelding S.V. et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin. Endocrinol. 39:1993;351-355.
48. Saad M.F., Knowler W.C., Pettitt D.J., Nelson R.G., Charles M.A., Bennett P.H. A two-step model for development of non-insulin-dependent diabetes. Am. J. Med. 90:1991;229-235.
49. Shoupe D., Kumar D.D., Lobo R.A. Insulin resistance in polycystic ovary syndrome. Am. J. Obstet. Gynecol. 147:1983;588-592.
50. Velazquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 43:1994;647-654.
51. Velazquez E., Acosta A., Mendoza S.G. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet. Gynecol. 90:1997;392-395.
52. Warram J.H., Martin B.C., Krolewski A.S., Soeldner J.S., Kahn C.R. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann. Int. Med. 113:1990;909-915.
53. Willis D., Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J. Clin. Endocrinol. Metab. 80:1995;3788-3790.
54. Willis D., Mason H., Gilling-Smith C., Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J. Clin. Endocrinol. Metab. 81:1996;302-309.